tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2020 Jun 19;7(8)
faa240.
doi: 10.1093/ofid/ofaa240. eCollection 2020 Aug.
Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study
Lidija Lepen[SUP] 1 [/SUP], Rok Blagus[SUP] 2 [/SUP], Maša Velušček[SUP] 1 [/SUP], Rajko Saletinger[SUP] 1 [/SUP], Miroslav Petrovec[SUP] 3 [/SUP], Fajko F Bajrović[SUP] 4 [/SUP], Daša Stupica[SUP] 1 5 [/SUP]
Affiliations
Abstract
Background: The efficacy and optimal duration of postexposure influenza prophylaxis with oseltamivir are undetermined in hospital settings, where immediate separation from index cases is not feasible.
Methods: In an open-label noninferiority randomized clinical trial in a single-center university hospital, the efficacy of 5-day vs 10-day postexposure prophylaxis with oseltamivir was compared in adult patients exposed to influenza who could not be immediately separated from index influenza cases. Influenza incidence was assessed for 10 days after discontinuing prophylaxis.
Results: Among 222 exposed patients (median age, 75 years; male 119; median Charlson Comorbidity Index, 5), 110 patients were assigned to 5 days of postexposure prophylaxis with oseltamivir, and 112 patients were assigned to the 10-day group. The median duration of exposure to influenza (interquartile range) was 2 (1-3) days. In the intention-to-treat analysis, the incidence of influenza was 2/110 (1.8%) in the 5-day group and 0/112 (0%) in the 10-day group (difference, 1.8 percentage points; 1-sided 95% CI, -1 to 4.9 percentage points; P = .77).
Conclusions: For patients exposed to influenza in a hospital setting and who were not immediately separated from index cases, postexposure prophylaxis with oseltamivir resulted in low incidence of nosocomial influenza transmission. Five-day postexposure prophylaxis was noninferior to 10-day regimen.
Clinicaltrialsgov registration: NCT03899571.
Keywords: chemoprophylaxis; infection control; influenza; neuraminidase inhibitor.
. 2020 Jun 19;7(8)
faa240.doi: 10.1093/ofid/ofaa240. eCollection 2020 Aug.
Five-Day vs 10-Day Postexposure Chemoprophylaxis With Oseltamivir to Prevent Hospital Transmission of Influenza: A Noninferiority Randomized Open-Label Study
Lidija Lepen[SUP] 1 [/SUP], Rok Blagus[SUP] 2 [/SUP], Maša Velušček[SUP] 1 [/SUP], Rajko Saletinger[SUP] 1 [/SUP], Miroslav Petrovec[SUP] 3 [/SUP], Fajko F Bajrović[SUP] 4 [/SUP], Daša Stupica[SUP] 1 5 [/SUP]
Affiliations
- PMID: 32766383
- PMCID: PMC7397832
- DOI: 10.1093/ofid/ofaa240
Abstract
Background: The efficacy and optimal duration of postexposure influenza prophylaxis with oseltamivir are undetermined in hospital settings, where immediate separation from index cases is not feasible.
Methods: In an open-label noninferiority randomized clinical trial in a single-center university hospital, the efficacy of 5-day vs 10-day postexposure prophylaxis with oseltamivir was compared in adult patients exposed to influenza who could not be immediately separated from index influenza cases. Influenza incidence was assessed for 10 days after discontinuing prophylaxis.
Results: Among 222 exposed patients (median age, 75 years; male 119; median Charlson Comorbidity Index, 5), 110 patients were assigned to 5 days of postexposure prophylaxis with oseltamivir, and 112 patients were assigned to the 10-day group. The median duration of exposure to influenza (interquartile range) was 2 (1-3) days. In the intention-to-treat analysis, the incidence of influenza was 2/110 (1.8%) in the 5-day group and 0/112 (0%) in the 10-day group (difference, 1.8 percentage points; 1-sided 95% CI, -1 to 4.9 percentage points; P = .77).
Conclusions: For patients exposed to influenza in a hospital setting and who were not immediately separated from index cases, postexposure prophylaxis with oseltamivir resulted in low incidence of nosocomial influenza transmission. Five-day postexposure prophylaxis was noninferior to 10-day regimen.
Clinicaltrialsgov registration: NCT03899571.
Keywords: chemoprophylaxis; infection control; influenza; neuraminidase inhibitor.